Detection of AmpC beta-lactamase genes in clinical isolates of Escherichia coli in Kermanshah city

Aims and AmpC β-lactamases hydrolyze penicillins, cephalosporins and cephamycins and resist inhibition by clavulanate, sulbactam and tazobactam. In this study, has been paid to prevalence of AmpC beta-lactamase enzymes produced by Escherichia coli isolates from various hospitals of Kermanshah city.
Material and A total of 100 clinical isolates of Escherichia coli were collected from the city of Kermanshah and after identification screened by Disk diffusion agar method and combined disk for production AmpC beta-lactamase. The isolates that were phenotypic have features these enzymes tested by Multiplex PCR. Also resistance of ESBLs producing isolates to ciprofloxacin, amikacin, meropenem and azteronam was measured by Microdilution broth for determination MIC (Minimal inhibitor concentration).
In this study, 43% of clinical isolates were Ampc beta-lactamase producers, based on phenotypic. After most review by Multiplex PCR showed 44.1% of them has Ampc beta-lactamase gene.
Prevalence of AmpC beta-lactamase due to ineffective prescription of the third of generation cephalosporins has become a major challenge for the treatment of disease. Phenotypic tests and Molecular methods such as PCR the detection of beta-lactamases enzymes can be very useful. Although this study has shown a high prevalence of AmpC beta-lactamase the city of Kermanshah, which is major cause of the self use of antibiotics or lack of antibiogram before beginning treatment. Lack of knowledge about phenotypic and molecular methods can provoke the development of resistance of AmpC beta-lactamase.